NO307499B1 - Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine - Google Patents

Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine

Info

Publication number: NO307499B1
Authority: NO; Norway
Prior art keywords: hsv; glycoprotein; vaccine; preparation; herpes simplex
Prior art date: 1991-03-21

Application number

NO933343A

Other languages

English (en)

Norwegian (no)

Other versions

NO933343D0 (no

NO933343L (no

Inventor

Myriam Francotte

Jean-Paul Prieels

Moncef Mohamed Slaoui

Nathalie Marie- Garcon-Johnson

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-21

Filing date

1993-09-20

Publication date

2000-04-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO307499(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-09-20 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

1993-09-20 Publication of NO933343D0 publication Critical patent/NO933343D0/no

1993-09-20 Publication of NO933343L publication Critical patent/NO933343L/no

2000-04-17 Publication of NO307499B1 publication Critical patent/NO307499B1/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

NO933343A 1991-03-21 1993-09-20 Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine NO307499B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9105992A GB9105992D0 (en)	1991-03-21	1991-03-21	Vaccine
PCT/EP1992/000592 WO1992016231A1 (en)	1991-03-21	1992-03-17	HERPES SIMPLEX VACCINE COMPRISING HSV GLYCOPROTEIN gD AND 3 dEACYLATED MONOPHOSPHORYL LIPID A

Publications (3)

Publication Number	Publication Date
NO933343D0 NO933343D0 (no)	1993-09-20
NO933343L NO933343L (no)	1993-09-20
NO307499B1 true NO307499B1 (no)	2000-04-17

Family

ID=10691946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO933343A NO307499B1 (no)	1991-03-21	1993-09-20	Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine

Country Status (34)

Country	Link
US (1)	US6027730A (es)
EP (1)	EP0576478B2 (es)
JP (1)	JP3530526B2 (es)
KR (1)	KR100224329B1 (es)
CN (2)	CN1058191C (es)
AP (1)	AP298A (es)
AT (1)	ATE129160T1 (es)
AU (1)	AU650521B2 (es)
BR (1)	BR9205745A (es)
CA (1)	CA2106492C (es)
CY (1)	CY1936A (es)
CZ (1)	CZ280505B6 (es)
DE (1)	DE69205566T3 (es)
DK (1)	DK0576478T4 (es)
ES (1)	ES2081102T5 (es)
FI (1)	FI107881B (es)
GB (1)	GB9105992D0 (es)
GR (1)	GR3017884T3 (es)
HK (1)	HK1004525A1 (es)
HU (1)	HU218025B (es)
IE (1)	IE69560B1 (es)
IL (1)	IL101290A (es)
MA (1)	MA22471A1 (es)
MX (1)	MX9201245A (es)
MY (1)	MY110086A (es)
NO (1)	NO307499B1 (es)
NZ (1)	NZ242057A (es)
PL (1)	PL170059B1 (es)
PT (1)	PT100262B (es)
SA (1)	SA92120459B1 (es)
SK (1)	SK279190B6 (es)
WO (1)	WO1992016231A1 (es)
YU (1)	YU28392A (es)
ZA (1)	ZA922011B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
US6197311B1 (en)	1991-07-25	2001-03-06	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) *	1992-02-12	1992-03-25	Smithkline Beecham Biolog	Vaccines
US6620414B2 (en)	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
CA2156525A1 (en) *	1993-02-19	1994-09-01	Susan Dillon	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DK0812593T4 (da) *	1993-03-23	2008-05-13	Smithkline Beecham Biolog	Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
RU2160119C2 (ru) *	1993-05-25	2000-12-10	Американ Цианамид Компани	Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (варианты)
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US7090842B1 (en)	1994-12-28	2006-08-15	Board Of Trustees Of The University Of Kentucky	Murine monoclonal anti-idiotype antibody 3H1 sequences for human carcinoembryonic antigen
US6949244B1 (en)	1995-12-20	2005-09-27	The Board Of Trustees Of The University Of Kentucky	Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6235280B1 (en)	1996-04-12	2001-05-22	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en)	1996-04-12	2002-04-11	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en)	1996-12-05	2002-10-22	Quadrant Healthcare (Uk) Limited	Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en)	1997-06-13	2001-08-14	Malaya Chatterjee	Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en)	1997-11-17	2002-03-12	University Of Kentucky Research Foundation	Methods and compositions for the treatment of psoriasis
GB9819898D0 (en) *	1998-09-11	1998-11-04	Smithkline Beecham Plc	New vaccine and method of use
US6692752B1 (en) *	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
KR100629028B1 (ko)	1998-10-16	2006-09-26	글락소스미스클라인 바이오로지칼즈 에스.에이.	애쥬번트 시스템 및 백신
US7026155B2 (en)	1999-02-02	2006-04-11	Regents Of The University Of California	Method of reducing bacterial proliferation
EP1104767A1 (en)	1999-11-30	2001-06-06	Stichting Dienst Landbouwkundig Onderzoek	Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups
US9273326B2 (en)	2004-04-30	2016-03-01	The Brigham And Women's Hospital, Inc.	Tetracycline-regulated gene expression in HSV-1 vectors
WO2006032475A2 (en)	2004-09-22	2006-03-30	Glaxosmithkline Biologicals S.A.	Staphylococcal immunogenic compositions
US20090081253A1 (en)	2005-03-23	2009-03-26	Glaxosmithkline Biologicals S.A.	Composition
TR201900418T4 (tr)	2005-12-22	2019-02-21	Glaxosmithkline Biologicals Sa	Pnömokok polisakkarit konjugat aşısı.
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
US20100021503A1 (en)	2006-03-30	2010-01-28	Glaxosmithkline Biologicals S.A.	Immunogenic composition
MX2009000660A (es)	2006-07-17	2009-04-08	Glaxosmithkline Biolog Sa	Vacuna de influenza.
DK2468300T3 (da)	2006-09-26	2018-01-29	Infectious Disease Res Inst	Vaccinesammensætning indeholdende syntetisk adjuvant
US20090181078A1 (en) *	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
US9452209B2 (en)	2007-04-20	2016-09-27	Glaxosmithkline Biologicals Sa	Influenza vaccine
KR101579947B1 (ko)	2007-06-26	2015-12-28	글락소스미스클라인 바이오로지칼즈 에스.에이.	스트렙토코쿠스 뉴모니애 캡슐 다당류 컨쥬게이트를 포함하는 백신
AU2010249330B2 (en)	2009-05-22	2015-11-05	Genocea Biosciences Inc.	Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
TWI494125B (zh)	2009-06-05	2015-08-01	Infectious Disease Res Inst	合成的葡萄吡喃糖基脂質佐劑
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
CN102666843B (zh) *	2009-12-21	2014-10-22	布里格海姆妇女医院公司	单纯疱疹病毒疫苗
CA2856697A1 (en)	2010-11-24	2012-06-07	Genocea Biosciences, Inc.	Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6309274B2 (ja) *	2011-03-11	2018-04-11	ターンストーン・リミテッド・パートナーシップ	ヒストンデアセチラーゼ阻害剤を含むワクチン接種法
SG194083A1 (en)	2011-04-08	2013-11-29	Immune Design Corp	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2747779A4 (en)	2011-08-22	2015-04-08	Nanobio Corp	VACCINE AGAINST HERPES SIMPLEX VIRUS IN THE FORM OF NANOEMULSION
WO2013078299A1 (en)	2011-11-23	2013-05-30	Genocea Biosciences, Inc.	Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
JP6619648B2 (ja)	2012-05-16	2019-12-11	イミューンデザインコーポレイション	Ｈｓｖ−２のためのワクチン
JP6469585B2 (ja)	2013-01-07	2019-02-13	バイオメディカルリサーチモデルズ，インコーポレイテッド	単純ヘルペスウイルス２型感染を処置するための治療用ワクチン
SG11201508092YA (en)	2013-04-18	2015-10-29	Immune Design Corp	Gla monotherapy for use in cancer treatment
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
EP3519427A4 (en)	2016-09-28	2020-03-11	Genocea Biosciences Inc.	METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
US11390650B2 (en)	2018-02-05	2022-07-19	The Brigham And Women's Hospital, Inc.	Recombinant Herpes Simplex Virus-2 expressing glycoprotein B and D antigens
US20220226465A1 (en)	2021-01-18	2022-07-21	ConserV Bioscience	Coronavirus Immunogenic Compositions, Methods and Uses Thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4372945A (en) *	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en) *	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) *	1981-12-24	1992-05-05	Health Research, Incorporated	Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) *	1982-02-18	1988-08-09	University Patents, Inc.	Materials and methods for herpes simplex virus vaccination
US5149660A (en) *	1982-02-18	1992-09-22	University Patents, Inc.	Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) *	1983-08-30	1991-08-27	Genentech Inc	Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) *	1984-04-06	1992-12-15	Chiron Corporation	Recombinant herpes simplex gb-gd vaccine
US5244792A (en) *	1984-04-06	1993-09-14	Chiron Corporation	Expression of recombinant glyoprotein B from herpes simplex virus
US4877611A (en) *	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US5554372A (en) *	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
EP0289550B1 (en) *	1986-10-20	1996-04-10	Chiron Corporation	Vaccine for use in the therapeutic treatment of hsv
US5149529A (en) *	1988-04-08	1992-09-22	Board Of Trustees Of Leland Chiron Corporation	Compositions and treatment for herpes simplex
US4912094B1 (en) *	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
NZ230424A (en) *	1988-08-25	1992-05-26	Liposome Co Inc	Liposomal composition comprising an externally disposed antigen
WO1990004412A1 (en) *	1988-10-27	1990-05-03	Regents Of The University Of Minnesota	Liposome immunoadjuvants containing il-2
US5597573A (en) *	1989-05-04	1997-01-28	Igen, Inc.	Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) *	1989-07-21	1992-10-27	Wisconsin Alumni Research Foundation	Method of stimulating the immune systems of animals and compositions useful therefor
AU651949B2 (en) *	1989-07-14	1994-08-11	American Cyanamid Company	Cytokine and hormone carriers for conjugate vaccines
ES2144400T3 (es) *	1990-08-01	2000-06-16	Res Corp Technologies Inc	Gen que codifica la gliproteina d del virus del herpes equino de tipo 1, su producto genico, anticuerpos y su utilizacion.
EP0541692B1 (en) *	1990-08-02	1999-05-06	Chiron Corporation	Herpes simplex virus vp16 vaccines
GB9106048D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccines
US5196452A (en) *	1991-01-29	1993-03-23	Genelabs Incorporated	Macrocyclic anti-viral compound and method
US5166173A (en) *	1991-01-29	1992-11-24	Genelabs Incorporated	Method of treating herpes simplex virus infection
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
MY111880A (en) *	1992-03-27	2001-02-28	Smithkline Beecham Biologicals S A	Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
EP0761231B1 (en) *	1992-06-25	2000-01-12	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Vaccine composition containing adjuvants
CA2156525A1 (en) *	1993-02-19	1994-09-01	Susan Dillon	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
DK0812593T4 (da) *	1993-03-23	2008-05-13	Smithkline Beecham Biolog	Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryllipid-A
RU2160119C2 (ru) *	1993-05-25	2000-12-10	Американ Цианамид Компани	Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (варианты)

1991
- 1991-03-21 GB GB9105992A patent/GB9105992D0/en active Pending
1992
- 1992-03-17 JP JP50598492A patent/JP3530526B2/ja not_active Expired - Lifetime
- 1992-03-17 WO PCT/EP1992/000592 patent/WO1992016231A1/en active IP Right Grant
- 1992-03-17 DK DK92906441T patent/DK0576478T4/da active
- 1992-03-17 DE DE69205566T patent/DE69205566T3/de not_active Expired - Lifetime
- 1992-03-17 CZ CS931958A patent/CZ280505B6/cs not_active IP Right Cessation
- 1992-03-17 SK SK946-93A patent/SK279190B6/sk unknown
- 1992-03-17 HU HU9302645A patent/HU218025B/hu unknown
- 1992-03-17 BR BR9205745A patent/BR9205745A/pt not_active Application Discontinuation
- 1992-03-17 AT AT92906441T patent/ATE129160T1/de active
- 1992-03-17 EP EP19920906441 patent/EP0576478B2/en not_active Expired - Lifetime
- 1992-03-17 AU AU13657/92A patent/AU650521B2/en not_active Expired
- 1992-03-17 CA CA 2106492 patent/CA2106492C/en not_active Expired - Lifetime
- 1992-03-17 CY CY193692A patent/CY1936A/xx unknown
- 1992-03-17 PL PL92300617A patent/PL170059B1/pl unknown
- 1992-03-17 ES ES92906441T patent/ES2081102T5/es not_active Expired - Lifetime
- 1992-03-17 KR KR1019930702835A patent/KR100224329B1/ko not_active IP Right Cessation
- 1992-03-18 MY MYPI92000448A patent/MY110086A/en unknown
- 1992-03-19 NZ NZ242057A patent/NZ242057A/en not_active IP Right Cessation
- 1992-03-19 IE IE920881A patent/IE69560B1/en not_active IP Right Cessation
- 1992-03-19 CN CN92102950A patent/CN1058191C/zh not_active Expired - Lifetime
- 1992-03-19 IL IL10129092A patent/IL101290A/en not_active IP Right Cessation
- 1992-03-19 MA MA22760A patent/MA22471A1/fr unknown
- 1992-03-19 PT PT100262A patent/PT100262B/pt not_active IP Right Cessation
- 1992-03-19 ZA ZA922011A patent/ZA922011B/xx unknown
- 1992-03-20 YU YU28392A patent/YU28392A/sh unknown
- 1992-03-20 MX MX9201245A patent/MX9201245A/es unknown
- 1992-03-20 AP APAP/P/1992/000368A patent/AP298A/en active
- 1992-04-21 SA SA92120459A patent/SA92120459B1/ar unknown
1993
- 1993-09-20 NO NO933343A patent/NO307499B1/no not_active IP Right Cessation
- 1993-09-21 FI FI934134A patent/FI107881B/fi not_active IP Right Cessation
1994
- 1994-09-09 US US08/303,542 patent/US6027730A/en not_active Expired - Lifetime
1995
- 1995-10-25 GR GR950402992T patent/GR3017884T3/el unknown
1998
- 1998-01-05 CN CN98103933A patent/CN1101226C/zh not_active Expired - Lifetime
- 1998-04-28 HK HK98103623A patent/HK1004525A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL101290A0 (en)	1992-11-15
DE69205566T3 (de)	2002-09-05
MX9201245A (es)	1992-10-01
AP9200368A0 (en)	1992-04-30
KR100224329B1 (ko)	1999-10-15
ES2081102T5 (es)	2001-09-01
CN1201692A (zh)	1998-12-16
JP3530526B2 (ja)	2004-05-24
PT100262A (pt)	1993-06-30
SK279190B6 (sk)	1998-07-08
YU28392A (sh)	1994-11-15
SK94693A3 (en)	1994-05-11
CY1936A (en)	1992-03-17
PT100262B (pt)	2001-05-31
CA2106492A1 (en)	1992-09-22
AU1365792A (en)	1992-10-21
CA2106492C (en)	2003-12-09
ES2081102T3 (es)	1996-02-16
EP0576478B2 (en)	2001-04-18
FI107881B (fi)	2001-10-31
DE69205566T2 (de)	1996-04-18
AP298A (en)	1994-01-14
CZ280505B6 (cs)	1996-02-14
EP0576478A1 (en)	1994-01-05
CN1101226C (zh)	2003-02-12
ATE129160T1 (de)	1995-11-15
WO1992016231A1 (en)	1992-10-01
HUT67052A (en)	1995-01-30
CZ195893A3 (en)	1994-07-13
NZ242057A (en)	1993-12-23
DE69205566D1 (en)	1995-11-23
PL170059B1 (pl)	1996-10-31
MA22471A1 (fr)	1992-10-01
JPH06505727A (ja)	1994-06-30
GR3017884T3 (en)	1996-01-31
SA92120459B1 (ar)	2005-06-14
NO933343D0 (no)	1993-09-20
MY110086A (en)	1997-12-31
DK0576478T3 (da)	1995-12-04
BR9205745A (pt)	1994-10-18
CN1065997A (zh)	1992-11-11
IE920881A1 (en)	1992-09-23
AU650521B2 (en)	1994-06-23
DK0576478T4 (da)	2001-07-23
FI934134L (fi)	1993-09-21
US6027730A (en)	2000-02-22
IE69560B1 (en)	1996-10-02
FI934134A0 (fi)	1993-09-21
HU218025B (hu)	2000-05-28
NO933343L (no)	1993-09-20
GB9105992D0 (en)	1991-05-08
EP0576478B1 (en)	1995-10-18
IL101290A (en)	1996-07-23
ZA922011B (en)	1993-01-27
HK1004525A1 (en)	1998-11-27
CN1058191C (zh)	2000-11-08
HU9302645D0 (en)	1994-01-28

Publication	Publication Date	Title
NO307499B1 (no)	2000-04-17	Vaksineformulering omfattende Herpes simplex (HSV) glykoprotein gD og 3 deacetylert monofosforyllipid A, anvendelse av HSV glykoprotein gD og fremgangsmÕte for fremstilling av vaksine
DK0689454T4 (da)	2005-05-30	Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A
KR900011476A (ko)	1990-08-01	백신 제제
HU9303282D0 (en)	1994-03-28	Pharmaceutical preparations containing hialuronic acid and/or derivatives and/or fragments
MX17752A (es)	1993-12-01	Formulaciones farmaceuticas y procedimiento para prepararlas
HU9303283D0 (en)	1994-03-28	Pharmaceutical preparations containing hialuronic acid and/or derivatives and/or fragments
DE3275904D1 (en)	1987-05-07	Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
FI891145A0 (fi)	1989-03-09	Menetelmä antiviraalisten ja immunostimuloivien farmaseuttisten koostumusten valmistamiseksi
IL99851A0 (en)	1992-08-18	Muramyldipeptide derivatives and influenza vaccine containing them
AU1631188A (en)	1988-11-24	Newcastle disease virus vaccine and method for the application thereof
AU5695686A (en)	1986-10-23	Immunogenic antigen-carrier protein conjugate for use in a vaccine against malaria
PT87776A (pt)	1989-05-31	Aminocyclopentyl ethers and their preparation and pharmaceutical formulation
AU5252090A (en)	1990-10-11	Improvements in and relating to pharmaceutical formulations
AU3614493A (en)	1993-09-01	Non-toxic lipid vaccine formulations
AU5531494A (en)	1994-06-22	Lipid containing formulation and method for its preparation
AU586299B2 (en)	1989-07-06	Vaccine against mumps and process for its preparation
AU2971692A (en)	1993-06-03	Flystrike antigen and vaccine and method for preparation
IL81650A0 (en)	1987-09-16	Purified human angiogenic factor,method for its preparation and pharmaceutical preparations
AU6224990A (en)	1991-03-21	Dihydrocaffeic acid derivatives and pharmaceutical preparations containing same
IL102290A0 (en)	1993-01-14	Ccv vaccine and its preparation
AU3565289A (en)	1989-11-29	Immunogenic complex and its use in vaccination
EP0268389A3 (en)	1988-09-21	Cyclopenthyl ethers and their preparation and pharmaceutical formulation
ZA89753B (en)	1989-08-30	Anti-herpes vaccine and pharmaceutical compositions
SG168394G (en)	1995-06-16	Method and formulation for orally administering bioactive agents to and through the peyer's patch
RO101947B1 (en)	1992-07-01	Marek's disease vaccine and preparation method

Legal Events

Date	Code	Title	Description
2012-04-10	MK1K	Patent expired